1. COMMIT/CCS-2 major efficacy results
End point
Clopidogrel (n=22 958) (%)
Placebo (n=22 891) (%)
Relative risk reduction (%) p
Death/
re-MI/stroke
9.3
10.1 9
2p=0.002
Death
7.7
8.1 7
2p=0.03
Re-MI
2.1
2.4 13
2p=0.02
Stroke
0.9
1.1 14
2p>0.1
Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

2. COMMIT/CCS-2 major bleeding
Type of major bleed
Clopidogrel (n)
Placebo (n)
Cerebral fatal 39 40
Cerebral nonfatal 16 15
Noncerebral fatal 36 37
Noncerebral nonfatal 46
Any major bleed
134 (0.58%)
124 (0.54%)
Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

3. Primary composite end point (death/re-MI/stroke) by delay
Hours to entry
Clopidogrel (%)
Placebo (%)
0-6
9.3
10.9
7-12
9.7
10.7
13-24
8.8
8.7
Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

4. Primary composite end point (death/ re-MI/stroke) by thrombolysis
Lytic given
Clopidogrel (%)
Placebo (%)
Yes
8.8
9.9 No
9.7
10.3
Chen Z. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.

5. Some of the major differences between COMMIT and CLARITY
Characteristic
COMMIT
CLARITY
Patients (n)
46 000
3500
Major end point
Mortality/
re-MI/stroke
Infarct patency
Hours since MI symptom onset
<24
<12
Age
Up to 10O years
Up to 75 years
Loading dose given No
Yes
Thrombolysis
Half of patients
All patients
Duration of clopidogrel treatment
2-3 weeks
2-3 days
Follow-up PCI
Very few patients
Two thirds of patients
Cannon C. American College of Cardiology 2005 Scientific Sessions; March 6-9, 2005; Orlando, FL.